Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeFirst stated

Joint Research and Development of Next-Generation VHH Antibodies With Epsilon Molecular Engineering

First written in FY2023. . Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
EMEとの産婦人科領域向けヒト化VHH抗体共同研究A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023First statedAnnual report

    「2023年２月には、株式会社 Epsilon Molecular Engineering（以下 「EME」）と、EME 独自のヒト化VHHスクリーニングプラットフォーム”The Month”を用いた産婦人科療領域における次世代VHH抗体の新薬創出を目的とした共同研究開発契約を締結しました。」

    EMEと独自のヒト化VHHスクリーニングプラットフォームを用いた産婦人科領域の共同研究開発契約を2023年2月に締結した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.